drugset / Trial / NCT05467254
Evaluate the Safety and Efficacy of CLL1+CD33 CAR-T in Patients With R/R AML
NaSingle-groupOpen-labelTreatment
Summary
This is an open label, phase I study to assess the safety and efficacy of CLL1+CD33 CAR-T in patients with relapsed and refractory acute myeloid leukemia
Timeline
- Start
- 2022-08-02
- Primary completion
- 2024-08-02
- Completion
- 2025-08-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CLL-1, CD33 and/or CD123-specific CAR gene-engineered T cells | Cell therapy | 3 cells/kg | — |
| Subject | CLL-1, CD33 and/or CD123-specific CAR gene-engineered T cells | Cell therapy | 6 cells/kg | — |
| Subject | CLL-1, CD33 and/or CD123-specific CAR gene-engineered T cells | Cell therapy | 9 cells/kg | — |